A new and experimental immunotherapy treatment has appeared successful in treating patients with multiple myeloma in an ongoing phase 1/2 clinical trial. The blood cancer treatment has seen successful response rates in 73% of patients, and an application has been submitted to the FDA to bring the drug to market.
Ook interessant voor je
Keytruda plus Lenvima demonstrates long-term, durable survival benefit versus sunitinib as first-line treatment for patients with advanced RCC
First-line treatment for patients with advanced RCC “Keytruda plus Lenvima continues to demonstrate durable clinical benefit as a first-line treatment for patients with advanced renal cell carcinoma, as shown by the...
10 x gelezen
Tradipitant Prevents Motion Sickness in Phase 3 Trail
Tradipitant Prevents Motion Sickness in Phase 3 Trail Tradipitant was found to be superior to placebo in preventing vomiting associated with motion sickness, according to results from a phase 3 study. The double-blind...
Resiniferatoxin Gets Breakthrough Therapy Status for Knee Osteoarthritis Pain
Resiniferatoxin Gets Breakthrough Therapy Status for Knee Osteoarthritis Pain The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to resiniferatoxin for the treatment of pain associated...